Skip to main content
. 2022 Jun 29;8(26):eabm9138. doi: 10.1126/sciadv.abm9138

Fig. 4. Kyn-CKA promotes anti-inflammatory actions in vivo.

Fig. 4.

(A to I) Kyn-CKA (50 mg/kg, ip, 30 min before challenge) inhibits NF-κB target gene expression 8 hours after LPS (10 mg/kg, ip). (J) Kyn-CKA inhibits KIM-1 8 hours following LPS. (K to P) Plasma cytokine levels modulated by Kyn-CKA 8 hours after LPS. Non-LPS–treated (n = 5) and LPS-treated (n = 8 to 9). *P < 0.05, **P < 0.01, and ***P < 0.001 by one-way ANOVA and Tukey’s test.